Motif Bio plc notes the announcement made today via RNS by Amphion Innovations plc that Amphion had reached an agreement in principle, subject to entering into a binding agreement, to extend the repayment of the loan facility by one year until 30 September 2019.
Motif Bio Notes Statement from Amphion Innovations
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, notes the announcement made today via RNS by Amphion Innovations plc (“Amphion”), a substantial shareholder in the Company, that Amphion had reached an agreement in principle, subject to entering into a binding agreement, to extend the repayment of the loan facility by one year until 30 September 2019. Amphion’s loan facility is secured by 24,475,591 ordinary shares of Motif Bio beneficially held by Amphion. Amphion currently owns a total of 25,254,611 ordinary shares of Motif Bio.
For further information please contact:
| Motif Bio plc | info@motifbio.com | |
| Graham Lumsden (Chief Executive Officer) | ||
| Peel Hunt LLP (NOMAD & BROKER) | + 44 (0)20 7418 8900 | |
| Dr. Christopher Golden | ||
| Oliver Jackson | ||
| Northland Capital Partners Limited (BROKER) | +44 (0)203 861 6625 | |
| David Hignell/Vadim Alexandre/Rob Rees | ||
| Walbrook PR Ltd. (UK FINANCIAL PR & IR) | +44 (0) 20 7933 8780 | |
| Paul McManus/Helen Cresswell/Lianne Cawthorne | ||
| MC Services AG (EUROPEAN IR) | +49 (0)89 210 2280 | |
| Raimund Gabriel | raimund.gabriel@ | |
| Solebury Trout (U.S. IR) | + 1 (646) 378-2963 | |
| Meggie Purcell | mpurcell@ | |
| Russo Partners (U.S. PR) | +1 (858) 717-2310 or +1 (212) 845 4272 | |
| David Schull | david.schull@russopartnersllc. | |
| Travis Kruse, Ph.D. | travis.kruse@russopartnersllc. | |
